Aravax, a clinical-stage biotechnology company headquartered in Melbourne, Australia and Oxford, UK, announced receipt of US FDA Fast Track Designation for PVX108, a peanut allergen-derived T cell epitope peptide immunotherapy, for the treatment of peanut allergy.
PVX108 is designed to engage allergen-specific CD4+ T cells directly via major histocompatibility complex (MHC) class II antigen presentation, bypassing immunoglobulin E (IgE)-mediated mast cell and basophil activation. Because the synthetic peptides are too short to cross-link IgE on effector cells, the approach is intended to induce immune tolerance while potentially reducing the treatment-induced allergic-reaction risk associated with whole-allergen immunotherapy. The only peanut allergen-specific immunotherapy, Palforzia, requires a prolonged dose-escalation schedule and carries a treatment emergent allergic reaction risk — a profile that PVX108's T cell-directed mechanism is designed to circumvent.
Published clinical evidence comes from a randomized, double-blind, placebo-controlled Phase I trial (ACTRN12617000692336) reported in Allergy in February 2024. That study recorded zero treatment-related hypersensitivity adverse events in the active arm, with only mild, transient injection-site reactions observed more frequently than in the placebo group. Exploratory immunological analyses at Week 21 and Month 18 post-treatment indicated durable shifts in allergen-specific T cell populations and increased peanut-specific IgG4 production, directional changes consistent with immune tolerance induction. The study was not designed to establish clinical efficacy, and it did not evaluate whether treatment increased the amount of peanut participants could tolerate.
An international Phase II trial (NCT05621317) is ongoing across sites in the US and Australia, with key data anticipated later in 2026, according to Aravax. The Fast Track Designation makes PVX108 eligible for rolling review, allowing completed sections of a future New Drug Application (NDA) to be submitted as they are finalized, and enables more frequent interactions with the FDA during development.